Medical News / Coverage ASRS 2019: Chirag Jhaveri, MD: 96-Week Visual and Anatomical Outcomes of Brolucizumab

Heading into the 2019 American Society of Retina Specialists Annual Meeting, sessions and studies pertaining to brolucizumab were an item on the radar of many retina specialists in the constant search for treatments to improve the vision and quality of life for patients. 

 As such, the presentation by Chirag Jhaveri, MD, assistant professor of ophthalmology at the University of Texas Dell Medical School, on the 96-week expanded anatomical and visual outcomes of the HAWK and HARRIER trials was one of the most anticipated sessions of the conference. Source: MDmag By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization

read more

Developing a greater understanding of associations and risk factors, even among common conditions, can pay great ... read more
A new era in the treatment of age-related macular degeneration could be on the horizon, as ... read more
Mixed in with the massive screens and eye-catching displays of the various companies use to represent ... read more
A new study examining the impact of guideline changes in Europe is suggesting use of topical ... read more